Literature DB >> 7670647

Plasma neuropeptide Y and catecholamines in women and men with essential hypertension.

B Wocial1, H Ignatowska-Switalska, P Pruszczyk, P Jedrusik, A Januszewicz, M Lapinski, W Januszewicz, Z Zukowska-Grojec.   

Abstract

Neuropeptide-Y (NPY) is a peptide proposed to modulate the effect of the sympathetic nervous system on blood pressure control and contribute to the development of essential hypertension. To assess the possible influence of gender on its role, we evaluated plasma NPY, noradrenaline (NA) and adrenaline (A) concentrations in men and women with essential hypertension. No difference in NPY concentration was found between genders, but NPY concentration was elevated in both hypertensive men and women. NA levels were similar in all investigated hyper- and normotensives, while A was increased only in hypertensive men. These results suggest various patterns of sympatho-adrenal activity in gender subgroups of patients with essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7670647     DOI: 10.3109/08037059509077586

Source DB:  PubMed          Journal:  Blood Press        ISSN: 0803-7051            Impact factor:   2.835


  9 in total

1.  Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent.

Authors:  Edwin K Jackson; Zaichuan Mi; Stevan P Tofovic; Delbert G Gillespie
Journal:  Hypertension       Date:  2014-11-03       Impact factor: 10.190

Review 2.  NPY and stress 30 years later: the peripheral view.

Authors:  Dalay Hirsch; Zofia Zukowska
Journal:  Cell Mol Neurobiol       Date:  2012-01-24       Impact factor: 5.046

3.  The correlation between SNPs within the gene of adrenergic receptor and neuropeptide Y and risk of cervical vertigo.

Authors:  Jianlong Han; Jinliang Zuo; Dengsong Zhu; Chunzheng Gao
Journal:  J Clin Lab Anal       Date:  2017-12-02       Impact factor: 2.352

4.  Neuropeptide Y promoter polymorphism modifies effects of a weight-loss diet on 2-year changes of blood pressure: the preventing overweight using novel dietary strategies trial.

Authors:  Xiaomin Zhang; Qibin Qi; Jun Liang; Frank B Hu; Frank M Sacks; Lu Qi
Journal:  Hypertension       Date:  2012-09-10       Impact factor: 10.190

Review 5.  Neuropeptide Y and neurovascular control in skeletal muscle and skin.

Authors:  Gary J Hodges; Dwayne N Jackson; Louis Mattar; John M Johnson; J Kevin Shoemaker
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-07-01       Impact factor: 3.619

6.  Relationship of plasma neuropeptide Y with angiographic, electrocardiographic and coronary physiology indices of reperfusion during ST elevation myocardial infarction.

Authors:  Florim Cuculi; Neil Herring; Alberto R De Caterina; Adrian P Banning; Bernard D Prendergast; John C Forfar; Robin P Choudhury; Keith M Channon; Rajesh K Kharbanda
Journal:  Heart       Date:  2013-02-12       Impact factor: 5.994

7.  Neuropeptide Y Stimulates Proliferation and Migration of Vascular Smooth Muscle Cells from Pregnancy Hypertensive Rats via Y1 and Y5 Receptors.

Authors:  Ping Zhang; Ying-Xin Qi; Qing-Ping Yao; Xiao-Hu Chen; Guo-Liang Wang; Bao-Rong Shen; Yue Han; Li-Zhi Gao; Zong-Lai Jiang
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

8.  Neuropeptide-Y causes coronary microvascular constriction and is associated with reduced ejection fraction following ST-elevation myocardial infarction.

Authors:  Neil Herring; Nidi Tapoulal; Manish Kalla; Xi Ye; Lyudmyla Borysova; Regent Lee; Erica Dall'Armellina; Christopher Stanley; Raimondo Ascione; Chieh-Ju Lu; Adrian P Banning; Robin P Choudhury; Stefan Neubauer; Kim Dora; Rajesh K Kharbanda; Keith M Channon
Journal:  Eur Heart J       Date:  2019-06-21       Impact factor: 29.983

9.  Neuropeptide Y-mediated sex- and afferent-specific neurotransmissions contribute to sexual dimorphism of baroreflex afferent function.

Authors:  Yang Liu; Di Wu; Mei-Yu Qu; Jian-Li He; Mei Yuan; Miao Zhao; Jian-Xin Wang; Jian He; Lu-Qi Wang; Xin-Jing Guo; Meng Zuo; Shu-Yang Zhao; Mei-Na Ma; Jun-Nan Li; Weinian Shou; Guo-Fen Qiao; Bai-Yan Li
Journal:  Oncotarget       Date:  2016-10-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.